A Study of Three Different Anti-HIV Drug Combinations in HIV-Infected Patients
NCT ID: NCT00002410
Last Updated: 2005-06-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
INTERVENTIONAL
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
TREATMENT
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Indinavir sulfate
Lamivudine
Zidovudine
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Exclusion Criteria
Excluded:
* Terfenadine, astemizole, cisapride, triazolam, or midazolam (competition for the enzyme cytochrome P-450 3A4 \[CYP3A4\] by indinavir could result in inhibition of metabolic breakdown of these drugs and create the potential for serious and/or life threatening events \[i.e., cardiac arrhythmia, prolonged sedation\]).
* Rifampin or rifabutin (prohibited because of potential drug interaction with indinavir).
* Ketoconazole, itraconazole, and clarithromycin.
* Concomitant systemic therapy for acute opportunistic infection or malignancy.
Excluded:
Life expectancy less than 12 months.
Prior Medication:
Excluded:
* Prior treatment with efavirenz, 3TC, an NNRTI, or an HIV protease inhibitor.
* Prior antiretroviral agent within 14 days of initiating study treatment.
* Prior treatment (within 30 days of initiating study treatment) with any other experimental drug for any indication.
Patients must:
* Have a diagnosis of HIV infection.
* Have CD4 counts greater than or equal to 50 cell/mm3.
* Have a life expectancy greater than or equal to 12 months.
* Be post-pubescent.
13 Years
60 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Dupont Merck
INDUSTRY
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Phoenix Body Positive
Phoenix, Arizona, United States
Arizona Clinical Research Ctr Inc
Tucson, Arizona, United States
Richard Stryker
Beverly Hills, California, United States
Paul Cimoch
Irvine, California, United States
AIDS Healthcare Foundation
Los Angeles, California, United States
Kraus Med Group
Los Angeles, California, United States
Oasis Clinic / Martin Luther Jr Gen Hosp / King-Drew Med Ctr
Los Angeles, California, United States
Blick Med Associates
Stamford, Connecticut, United States
Novum Inc
Washington D.C., District of Columbia, United States
Bach and Godofsky
Bradenton, Florida, United States
Community Research Initiative of South Florida
Coral Gables, Florida, United States
Boulevard Comprehensive Care Ctr
Jacksonville, Florida, United States
Larry Marc Bush / c/o Sally Yantis
Lake Worth, Florida, United States
Univ of Miami School of Medicine
Miami, Florida, United States
Ctr for Quality Care
Tampa, Florida, United States
Daniel Seekins
Tampa, Florida, United States
Infectious Disease Research Institute
Tampa, Florida, United States
Treasure Coast Infectious Disease Consultants
Vero Beach, Florida, United States
Georgia Research Associates
Atlanta, Georgia, United States
Med College of Georgia
Augusta, Georgia, United States
Infectious Diseases
Indianapolis, Indiana, United States
Univ of Kentucky Med Ctr
Lexington, Kentucky, United States
Kansas City AIDS Research Consortium
Kansas City, Missouri, United States
Univ of Nebraska Med Ctr / HIV Clinic
Omaha, Nebraska, United States
Univ Med Ctr / HIV Wellness Ctr
Las Vegas, Nevada, United States
Community Research Initiative on AIDS
New York, New York, United States
Clinical Directors Network / HIV/AIDS Program Manager
New York, New York, United States
Wake Forest Univ School of Medicine
Winston-Salem, North Carolina, United States
Remington-Davis Inc
Columbus, Ohio, United States
Philadelphia FIGHT
Philadelphia, Pennsylvania, United States
The Miriam Hosp
Providence, Rhode Island, United States
Research Services 2000 Inc
Dallas, Texas, United States
Division of Infectious Disease / Dept of Internal Medicine
Dallas, Texas, United States
Research Services 2000 Inc
Fort Worth, Texas, United States
Montrose Clinic
Houston, Texas, United States
UT-Health Science Ctr
Houston, Texas, United States
Diagnostic Clinic of San Antonio
San Antonio, Texas, United States
Oyster Point Med Specialists
Newport News, Virginia, United States
Novum Inc / Pharmaceutical Research Services
Seattle, Washington, United States
Infectious Diseases Associates
Milwaukee, Wisconsin, United States
Javier O Morales Ramirez
San Juan, , Puerto Rico
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DMP 266-006
Identifier Type: -
Identifier Source: secondary_id
281B
Identifier Type: -
Identifier Source: org_study_id